Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02081027
Other study ID # CIN001- Riluzole in Autism
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date September 19, 2013
Est. completion date May 2015

Study information

Verified date April 2017
Source Children's Hospital Medical Center, Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determine if riluzole shows evidence of efficacy, safety, and tolerability targeting drug-refractory irritability (DRI) in persons with autism spectrum disorders (ASD).


Description:

A randomized, double blind, placebo-controlled, 12-week cross-over study (5-week treatment periods with 2-week washout) of adjunctive riluzole in 12 persons with ASD and DRI between the ages of 12 and 25 years.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date May 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender All
Age group 12 Years to 25 Years
Eligibility Inclusion Criteria: - Age = 12 and < 26 years. - Weight greater than 50 kg. - Diagnosis of ASD - Drug-refractory irritability, as defined as screening ABC Irritability subscale (ABC-I) score of =18 AND 1) failure of clinically adequate treatment trials of both aripiprazole and risperidone or 2) failure of at least three previous clinically adequate drug trials targeting irritability (one trial must include aripiprazole or risperidone), as confirmed by caregiver reports and medical record review when available. - Stable dosing of all concomitant psychotropic medications (including those targeting irritability) for four weeks prior to screening visit and during the study. - Presence of parent/guardian willing to serve as informant for behavioral outcome measures and shipping control sample for Extracellular Signal-Related Kinase biomarker (ERK) assay. Exclusion Criteria: - Current use of more than two concomitant psychotropic drugs targeting irritability. - Current use of valproic acid. - Current use of drugs with known interaction with riluzole - Current use of drugs with concomitant glutamatergic or glutamatergic- modulating action medications. - For female subjects of child bearing potential, a positive serum pregnancy test. - History of pancreatitis. - Hemoglobin less than or equal to 8.0 gm/dL. - Neutropenia with absolute neutrophil count less than or equal to 1.0 K/mcL. - Problems with kidney functioning, as assessed by lab work - Any major chronic medical or chronic respiratory illness considered to be uncontrolled by the Principal Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Riluzole

Other:
placebo


Locations

Country Name City State
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Global Impression-Improvement A clinician-rated global assessment of symptom change rated on a scale from 1 to 7 Change from baseline to end of week 12
Primary Aberrant Behavior Checklist- Irritability A parent questionnaire measuring five behavioral domains Change between baseline and end of each phase
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02625116 - ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
Not yet recruiting NCT06381856 - Improving Participation of Autistic Children and Adolescents in the Habilitation Process
Recruiting NCT02280746 - Gluten for Autism Spectrum Disorders N/A
Completed NCT01945957 - Brain Imaging of Intranasal Oxytocin Treatment in Autism Phase 1
Completed NCT01661855 - A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD Phase 2
Completed NCT01780090 - Handheld Technology for Speech Development in Students With Autism N/A
Completed NCT01592747 - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Phase 2
Completed NCT01691066 - Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder N/A
Completed NCT01694667 - Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Phase 2
Active, not recruiting NCT01417026 - Intranasal Oxytocin and Learning in Autism Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT01695200 - Omega-3 Fatty Acids in Autism Spectrum Disorders Phase 4
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Not yet recruiting NCT00695812 - The Development of Younger Siblings of Children With Autism Now at 10 Years of Age N/A
Completed NCT01675414 - Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD) N/A
Recruiting NCT05910502 - Project AFECT (Autism Family Empowerment Coaching and Training Program) N/A
Completed NCT02797379 - The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders N/A
Terminated NCT01730079 - Near Infrared Spectroscopy in Children With Autism and ADHD
Completed NCT01603225 - Transcranial Direct Current Stimulation and Autism
Completed NCT01931033 - An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders N/A